[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].

Zheng, X W; Tao, G; Zhang, Y W; Yang, G N; Huang, P

Zheng, X W; Tao, G; Zhang, Y W; Yang, G N; Huang, P.

Zheng XW; Department of Pharmacy, Cancer Hospital of University of Chinese Academy of Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Tao G; Department of Oncology, Zhejiang Medical and Health Centre Hangzhou Hospital, Hangzhou 310022, China.
Zhang YW; Department of Pharmacy, Zhejiang Provincial People's Hospital(People's Hospital of Hangzhou Medical College), Hangzhou 310010, China.
Yang GN; Department of Pharmacy, Cancer Hospital of University of Chinese Academy of Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Huang P; Department of Pharmacy, Zhejiang Provincial People's Hospital(People's Hospital of Hangzhou Medical College), Hangzhou 310010, China.

Zhonghua Nei Ke Za Zhi ; 59(5): 400-404, 2020 May 01.

Article in Chinese | MEDLINE | ID: covidwho-3042

Subject(s)

Coronavirus Infections/drug therapy; Drug Interactions; Lopinavir/adverse effects; Neoplasms/drug therapy; Pneumonia, Viral/drug therapy; Ritonavir/adverse effects; Betacoronavirus; COVID-19; Drug Combinations; Drug Monitoring; Humans; Pandemics; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Ritonavir / Drug Interactions / Lopinavir / Neoplasms Limits: Humans Language: Chinese Journal: Zhonghua Nei Ke Za Zhi Year: 2020 Document Type: Article Affiliation country: Cma.j.cn112138-20200219-00097

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google